<DOC>
	<DOCNO>NCT00784810</DOCNO>
	<brief_summary>The purpose study compare oxycodone/naloxone combination tablet codeine/paracetamol tablet treatment moderate severe chronic low back pain pain due osteoarthritis .</brief_summary>
	<brief_title>A Study Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol Treatment Moderate Severe Chronic Low Back Pain Pain Due Osteoarthritis</brief_title>
	<detailed_description>This randomise , double-blind , double-dummy , parallel group , 12-week study ass efficacy tolerability oxycodone/naloxone compare codeine/paracetamol tablet treatment moderate severe chronic low back pain moderate severe pain due OA hip /or knee . The screening period 3 - 7 day duration . If subject meet screen criterion may enter Run-in Period . During screen period subject continue take pre-study pain medication . The run-in period 7 - 14 day duration . During run-in period subject continue take pre-study pain medication . Visit 3 occur end Run-in Period ( 7-14 day Visit 2 ) . To qualify entry treatment period study , subject must uncontrolled pain show average daily pain score &gt; 5 4 last 7 day run period . Eligible subject randomise either oxycodone/naloxone codeine/paracetamol tablet . Subjects receive double-blind study medication 12 week .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Codeine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>1 . Male female subject least 18 year old . 2 . Female subject less one year postmenopausal must negative urine pregnancy test record prior first dose study medication , nonlactating , willing use adequate reliable contraception throughout study . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly sterilization , implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomise partner . 3 . Subjects clinical diagnosis degenerative primary OA whose primary pain site hip ( ) and/or knee ( ) require aroundtheclock opioid therapy diagnosis may support evidence one following : MRI , CAT , arthroscopy xray . The clinical imaging OA may include one follow feature : joint space narrowing , degenerative change , osteophyte formation subchondral cyst . Subjects identify painful joint ( hip knee ) documentation OA . Pain measurement do joint . 4 . Subjects moderate severe chronic low back pain e.g osteoarthritis , spinal stenosis , spondylolisthesis , fail back surgery , scoliosis , discogenic disorder herniated disc . 5 . Subjects currently receive codeine/paracetamol combination tablet maximum dose 120 mg codeine per day tramadol maximum dose 100 mg/day dihydrocodeine / paracetamol tablet maximum dose 120 mg dihydrocodeine per day . 6 . Subjects willing able participate aspect core study , include use oral medication , completion subjective evaluation , attend schedule clinic visit , complete telephone contact , compliance protocol requirement evidence provide write , informed consent . 7 . Subjects prestudy , nonopioid analgesic , concomitant medication , include medication treatment depression anticipate remain stable throughout treatment phase study . 1 . Any history hypersensitivity oxycodone , naloxone , codeine , ibuprofen , bisacodyl related product ingredient . 2 . Any contraindication oxycodone , naloxone , codeine , paracetamol ibuprofen . 3 . Subjects evidence significant structural abnormality GI tract ( e.g. , bowel obstruction , stricture ) diseases/conditions affect bowel transit ( e.g. , ileus , hypothyroidism ) . 4 . Subjects cancer associate pain . 5 . Subjects secondary osteoarthritis ( e.g . fracture , septic , acromegaly etc. ) . 6 . Active alcohol drug abuse and/or history opioid abuse . 7 . Subjects Rheumatoid Arthritis . 8 . Subjects non opioid induce constipation . 9 . Subjects evidence clinically unstable disease , determine medical history , clinical laboratory test , ECG result , physical examination , investigator 's opinion , preclude entry study . 10 . Subjects evidence impair liver/kidney function upon entry study define : Aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase level &gt; 3 time upper limit normal ; Gamma glutamyl transpeptidase â‰¥5 time upper limit normal ; Total bilirubin level outside reference range unless value associate pre document Gilbert 's Syndrome ; Creatinine level outside reference range &gt; 2 mg/dl unless discussion Medical Monitor confirm subject renal impairment would preclude subject 's inclusion study ; In investigator 's opinion subject liver and/or kidney impairment extent subject participate study . 11 . Subjects require treatment diagnosis IBS . 12 . Subjects receive hypnotic CNS depressant , investigator 's opinion , may pose risk additional CNS depression opioid study medication . 13 . Subjects history depression psychiatric disorder opinion investigator significant enough exclude subject study . 14 . Subjects currently involved legal action regard pain condition subject pain condition may psychiatric nature . 15 . Subjects receive opioid substitution therapy opioid addiction ( e.g. , methadone buprenorphine ) . 16 . Subjects presently take , take naloxone naltrexone within 30 day study entry ( defined start Screening Period ) . 17 . Surgery within 2 month prior start Screening Period , plan surgery the12week treatment period may affect GI motility pain level . 18 . Subjects receive new chemical entity experimental drug within 30 day study entry ( define start Screening Period ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Efficacy , tolerability , moderate/severe , oxycodone/naloxone</keyword>
	<keyword>codeine/paracetamol , chronic low back pain , osteoarthritis</keyword>
</DOC>